Alzheimer’s Disease (AD), also called as just Alzheimer’s is a progressive neurodegenerative disease that ischaracterized by memory loss, disorientation, mood disorders, and behavioural changes. It commonly occursin people above the age of 65, but early cases can start as early as mid-30s. The current medications forAlzheimer’s are only palliative and include reversible cholinesterase inhibitors and Memantine, an NMDAantagonist. Various other drugs are also used to treat the behavioural and psychiatric changes that occur inthe later stages of the disease. Root extracts of Withaniasomnifera, commonly called as Ashwagandha, havebeen shown to have anti-Alzheimers activity, in silico, in-vitro and in-vivo. This activity of Ashwagandhais attributed mainly to 2 constituents; Withanosides and Withanolides. They are known to promote neurite
outgrowth, reduce Aβ toxicity, improve cognitive functions and also reduce cholinergic activity in the CNS,by inhibiting the enzyme acetyl cholinesterase.
KEYWORDS: Alzheimer’s, Ashwagandha, Withaniasomnifera, Withanoside, Withanolide